The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.

The result was redirect to Rimonabant. Neil (►) 11:26, 1 June 2007 (UTC)[reply]

Zimulti[edit]

Zimulti (edit | talk | history | protect | delete | links | watch | logs | views) – (View log)

Delete – this article is about a non-notable future name of an existing drug. An attempt to redirect to Rimonabant was reverted without explanation by the original editor, who may have a conflict of interest. ✤ JonHarder ^talk 13:01, 26 May 2007 (UTC)[reply]

• Redirect to Rimonabant. That's what Acomplia does, and even if the drug is never approved under this name, redirects are cheap. Deor 15:17, 26 May 2007 (UTC)[reply]
• Redirect to Rimonabant (without prejudice to reverting to present revision once the trade name has been approved). Caknuck 15:22, 26 May 2007 (UTC)[reply]

The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.